101 related articles for article (PubMed ID: 25450288)
1. Tumor M2-pyruvate kinase in stool as a biomarker for diagnosis of colorectal cancer: A meta-analysis.
Huang JX; Zhou Y; Wang CH; Yuan WW; Zhang ZD; Zhang XF
J Cancer Res Ther; 2014 Nov; 10 Suppl():C225-8. PubMed ID: 25450288
[TBL] [Abstract][Full Text] [Related]
2. The value of serum Cyfra21-1 as a biomarker in the diagnosis of patients with non-small cell lung cancer: a meta-analysis.
Cui C; Sun X; Zhang J; Han D; Gu J
J Cancer Res Ther; 2014 Nov; 10 Suppl():C131-4. PubMed ID: 25450270
[TBL] [Abstract][Full Text] [Related]
3. [Clinical significance of blood and fecal tumor M2-pyruvate kinase expression in patients with colorectal cancer].
Li Y; Wang JJ
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Dec; 31(12):2087-9. PubMed ID: 22200720
[TBL] [Abstract][Full Text] [Related]
4. A systematic review and meta-analysis of the diagnostic accuracy of pyruvate kinase M2 isoenzymatic assay in diagnosing colorectal cancer.
Uppara M; Adaba F; Askari A; Clark S; Hanna G; Athanasiou T; Faiz O
World J Surg Oncol; 2015 Feb; 13():48. PubMed ID: 25888768
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of secreted frizzled-related protein 2 gene promoter hypermethylation in stool for colorectal cancer: A meta-analysis.
Zhou Z; Zhang H; Lei Y
J Cancer Res Ther; 2016 Oct; 12(Supplement):30-33. PubMed ID: 27721248
[TBL] [Abstract][Full Text] [Related]
6. The diagnostic value of DNA hypermethylation in stool for colorectal cancer: a meta-analysis.
Qian LY; Zhang W
J Cancer Res Ther; 2014 Dec; 10 Suppl():287-91. PubMed ID: 25693937
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer antigen 3 as a biomarker in the urine for prostate cancer diagnosis: a meta-analysis.
Xue WJ; Ying XL; Jiang JH; Xu YH
J Cancer Res Ther; 2014 Nov; 10 Suppl():C218-21. PubMed ID: 25450286
[TBL] [Abstract][Full Text] [Related]
8. Tumor M2-pyruvate kinase as tumor marker in exocrine pancreatic cancer a meta-analysis.
Kumar Y; Gurusamy K; Pamecha V; Davidson BR
Pancreas; 2007 Aug; 35(2):114-9. PubMed ID: 17632316
[TBL] [Abstract][Full Text] [Related]
9. Tumor M2 pyruvate kinase in diagnosis of nonsmall cell lung cancer: A meta-analysis based on Chinese population.
Liu J; Zhu H; Jiang H; Zhang H; Wu D; Hu X; Zhang H
J Cancer Res Ther; 2015 Aug; 11 Suppl 1():C104-6. PubMed ID: 26323904
[TBL] [Abstract][Full Text] [Related]
10. Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: prospective multicenter study.
Shastri YM; Loitsch S; Hoepffner N; Povse N; Hanisch E; Rösch W; Mössner J; Stein JM
Am J Gastroenterol; 2008 Jun; 103(6):1496-504. PubMed ID: 18510609
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of different stool tests for the detection of cancer of the colon].
Vogel T; Driemel C; Hauser A; Hansmann A; Lange S; Jonas M; Möslein G
Dtsch Med Wochenschr; 2005 Apr; 130(14):872-7. PubMed ID: 15800820
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of circulating miR-21 for colorectal cancer: a meta-analysis.
Shan L; Ji Q; Cheng G; Xia J; Liu D; Wu C; Zhu B; Ding Y
Cancer Biomark; 2015; 15(1):47-56. PubMed ID: 25524942
[TBL] [Abstract][Full Text] [Related]
13. Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls.
Hardt PD; Toepler M; Ngoumou B; Rupp J; Kloer HU
Anticancer Res; 2003; 23(2A):851-3. PubMed ID: 12820312
[TBL] [Abstract][Full Text] [Related]
14. Fecal pyruvate kinase-M2 (tumor M2-PK) measurement: a new screening concept for colorectal cancer.
Ewald N; Schaller M; Bayer M; Akinci A; Bretzel RG; Kloer HU; Hardt PD
Anticancer Res; 2007; 27(4A):1949-52. PubMed ID: 17649802
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of fecal tumor M2-pyruvate kinase for CRC screening: a systematic review and meta-analysis.
Li R; Liu J; Xue H; Huang G
Int J Cancer; 2012 Oct; 131(8):1837-45. PubMed ID: 22261915
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic and prognostic value of tumor M2-pyruvate kinase levels in patients with colorectal canhcer.
Demır AS; Erdenen F; Müderrısoğlu C; Toros AB; Bektaş H; Gelışgen R; Tabak Ö; Altunoğlu E; Uzun H; Erdem Huq GE; Aral H
Turk J Gastroenterol; 2013; 24(1):36-42. PubMed ID: 23794342
[TBL] [Abstract][Full Text] [Related]
17. The accuracy of circulating microRNA-21 in the diagnosis of colorectal cancer: a systematic review and meta-analysis.
Xu F; Xu L; Wang M; An G; Feng G
Colorectal Dis; 2015 May; 17(5):O100-7. PubMed ID: 25683351
[TBL] [Abstract][Full Text] [Related]
18. Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: a meta-analysis.
Tonus C; Sellinger M; Koss K; Neupert G
World J Gastroenterol; 2012 Aug; 18(30):4004-11. PubMed ID: 22912551
[TBL] [Abstract][Full Text] [Related]
19. Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer.
Schneider J; Schulze G
Anticancer Res; 2003; 23(6D):5089-93. PubMed ID: 14981971
[TBL] [Abstract][Full Text] [Related]
20. Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia.
Shastri YM; Naumann M; Oremek GM; Hanisch E; Rösch W; Mössner J; Caspary WF; Stein JM
Int J Cancer; 2006 Dec; 119(11):2651-6. PubMed ID: 16929517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
